Boston Immune Technologies and Therapeutics
生物技术研究
Boston，Massachusetts 107 位关注者
BITT is developing multiple antibodies for indications in oncology, inflammation, autoimmunity and infectious disease
关于我们
BITT’s dominant antibody antagonist antibody platform (DOMabTM) is a proprietary discovery platform for the development of antagonist monoclonal antibodies to the TNF superfamily. DOMab antibodies create unique surface stabilization of anti-parallel dimers for altering intracellular signaling. For TNF superfamily proliferative pathways (such as TNFR2, TRAIL and HVEM), antagonism causes cell death. For death receptors (such as CD40, CD27 and OX40), antagonism permits cell growth. Our technology’s ability to create antibodies that target only rapidly proliferating cells opens the door to TNF superfamily targets that were previously considered undruggable or limited by toxicology.
- 网站
-
https://www.bostonimmunetech.com/
Boston Immune Technologies and Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Boston，Massachusetts
- 类型
- 私人持股
地点
-
主要
获取路线
50 Milk Street
US，Massachusetts，Boston，02110